Testing HC-7366 with Belzutifan for kidney cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1b clinical trial evaluates the safety, tolerability, and efficacy of HC-7366 in combination with belzutifan (WELIREG™) in patients with locally advanced or metastatic renal cell carcinoma (RCC) that has a predominant clear cell component. The study is designed as a multicenter, open-label trial that includes a monotherapy cohort and a combination dose escalation and expansion. Approximately 80 patients will be enrolled to determine the maximum tolerated dose of HC-7366 when used alongside belzutifan, regardless of VHL gene mutation status.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component
* Be age 18 years or older (male or female) at the time of consent

Where it's running

• University of Arizona Cancer Center
  Tucson, Arizona, United States Recruiting
• University of California San Diego Moores Cancer Center
  La Jolla, California, United States Recruiting
• Cedars-Sinai Medical Center
  Los Angeles, California, United States Recruiting
• University of Colorado Anschutz Medical Campus
  Aurora, Colorado, United States Recruiting
• Rocky Mountain Cancer Centers, LLP
  Lone Tree, Colorado, United States Recruiting
• Yale - New Haven Hospital
  New Haven, Connecticut, United States Recruiting

Study contacts

• Study coordinator: Michele Gargano
• Email: mgargano@hibercell.com
• Phone: 651-675-0300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma DNA Methylation to Classify Kidney Masses Before Surgery

  This study tests a blood-based DNA methylation test to help distinguish malignant kidney cancers from benign kidney masses in adults who are planned for kidney surgery.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT07874542

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Intensified monitoring to personalize cabozantinib dosing in advanced kidney cancer

  We will test whether closer pharmacology-based monitoring helps people with advanced kidney cancer tolerate cabozantinib better while keeping its effect against the cancer.

  Recruiting Centro di Riferimento Oncologico - Aviano · Aviano, Pordenone · NCT07805122

• Who’s at high risk after RCC surgery? Real-world clues from French registry

  This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07753343

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.